In conclusion, SGLT2 inhibitors provide cardiovascular and renal protection in type 2 diabetes mellitus patients, with suppression of sympathetic overactivity being one of the less understood but critical processes. The gene discussed is SLC5A2; the disease is diabetes mellitus.